ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases
Enhertu demonstrated superior efficacy in treating HER2+ breast cancer brain metastases at ESMO 2024, outperforming Kadcyla. Enhertu's 12-month PFS was 61.6% with an ORR of 79% for CNS metastases, maintaining 90.3% OS in active BCBM patients. Analysts predict Enhertu will dominate the ADC market, reaching $11.2bn by 2030, while Kadcyla and Tukysa are projected to achieve $838m and $1.2bn respectively.
Reference News
Enhertu demonstrated superior efficacy in treating HER2+ breast cancer brain metastases at ESMO 2024, outperforming Kadcyla. Enhertu's 12-month PFS was 61.6% with an ORR of 79% for CNS metastases, maintaining 90.3% OS in active BCBM patients. Analysts predict Enhertu will dominate the ADC market, reaching $11.2bn by 2030, while Kadcyla and Tukysa are projected to achieve $838m and $1.2bn respectively.